INTRANASAL ADMINISTRATION

1 - 5 . (canceled)

6 . A method of delivering a protein formulation to the upper posterior region of a nasal cavity of a subject for uptake into the central nervous system (CNS) of the subject, the method comprising:

the subject exhaling through a mouthpiece unit to cause closure of the oropharyngeal velum of the subject; and

delivering the formulation through a nozzle of a nosepiece of a delivery device into the nasal cavity of the subject to provide for uptake of the protein to the CNS without triggering an immune response;

wherein the air exhaled from an exhalation breath is delivered through the nosepiece to entrain the protein formulation as delivered from the nozzle;

wherein the protein formulation comprises a solubilized protein formulation which includes a solubilizing agent which maintains the protein in solution following delivery.

7 . The method of claim 6 , wherein the nosepiece includes an agent which degrades polysaccharide components of endotoxins.

8 . The method of claim 6 , further comprising replacing the nosepiece following each delivery.

9 . The method of claim 6 , wherein the protein does not precipitate from solution owing to one or more of a shift in pH, ionic balance or osmolarity following delivery.

10 . The method of claim 6 , wherein the protein formulation includes an immunomodulator which acts to prevent an immune response to the protein.

11 . The method of claim 6 , wherein the protein is configured to degrade after about 5 minutes following delivery.

12 . The method of claim 11 , wherein the protein formulation includes a proteolytic agent or one or more of trypsin, chymotrypsin, N terminal peptidases or C terminal peptidases which acts to degrade the protein after delivery.

13 . The method of claim 6 , wherein the protein is configured for uptake from the olfactory region in the upper posterior region within about 5 minutes following delivery.

14 . The method of claim 13 , wherein the protein formulation includes an uptake agent or a cyclodextrin for providing for uptake of the protein from the olfactory region.

15 . The method of claim 6 , wherein the protein comprises insulin or an insulin analogue.

16 . The method of claim 6 , wherein the protein comprises an oxytocic hormone, carbetocin, demoxytocin, oxytocin or a pharmaceutically-acceptable derivative or analogue thereof.

17 . The method of claim 6 , wherein the protein comprises an oxytocin antagonist, atosiban or a pharmaceutically-acceptable derivative or analogue thereof.

18 . The method of claim 6 , wherein the protein comprises:

(i) an antidiurectic hormone, argipressin, lypressin, desmopressin, felypressin, ornipressin, terlipressin, vasopressin or a pharmaceutically-acceptable derivative or analogue thereof;

(ii) a corticotrophic hormone, corticotrophin, tetracosactide or a pharmaceutically-acceptable derivative or analogue thereof;

(iii) a corticotrophic releasing hormone, corticorelin or a pharmaceutically-acceptable derivative or analogue thereof;

(iv) an omatotrophic hormone, mecasermin, somtrem, somatropin or a pharmaceutically-acceptable derivative or analogue thereof;

(v) a somatotrophic hormone receptor antagonist, pegvisomant or a pharmaceutically-acceptable derivative or analogue thereof;

(vi) an omatotrophic releasing hormone, sermorelin, somatorelin or a pharmaceutically-acceptable derivative or analogue thereof;

(vii) a somatotrophic release inhibitor, lanreotide, octreotide, somatostatin, vapreotide or a pharmaceutically-acceptable derivative or analogue thereof;

(viii) a gonadotrophic hormone, choriogonadotrophin alfa, chorionic gonadotrophin, a follicle stimulating hormone, follitropin alfa, follitropin beta, a luteinising hormone, lutropin alfa, menotrophin, urofollitropin or a pharmaceutically-acceptable derivative or analogue thereof;

(ix) a gonadotrophic releasing hormone, buserelin, deslorelin, gonadorelin, goserelin, histrelin, leuprorelin, naferlin, triptorelin or a pharmaceutically-acceptable derivative or analogue thereof;

(x) an onadotrophic releasing hormone antagonist, abarelix, cetorelix, ganirelix or a pharmaceutically-acceptable derivative or analogue thereof;

(xi) a thyrotrophic hormone, thyrotrophin, thyrotrophin alfa or a pharmaceutically-acceptable derivative or analogue thereof;

(xii) a thyrotrophic releasing hormone, posatirelin, protirelin, taltirelin or a pharmaceutically-acceptable derivative or analogue thereof;

(xiii) a lactotrophic hormone, prolactin or a pharmaceutically-acceptable derivative or analogue thereof;

(xiv) a metabolic peptide, an insulin-like growth factor, a glucagon, a growth hormone, PYY3-36 or a pharmaceutically-acceptable derivative or analogue thereof;

(xv) a calcitonin, elcatonin, salcatonin or a pharmaceutically-acceptable derivative or analogue thereof;

(xvi) a melanocyte stimulating hormone;

(xvii) a nerve growth factor;

(xviii) an epidermal growth factor;

(xix) an epoetin or a pharmaceutically-acceptable derivative or analogue thereof;

(xx) an interleukin;

(xxi) a protein involved in one or both of blood coagulation and fibrinolysis; or

(xxii) an antibiotic.

19 . The method of claim 6 , wherein the protein is configured to degrade after about 10 minutes following delivery.

20 . The method of claim 6 , wherein the protein is configured to degrade after about 15 minutes following delivery.

21 . The method of claim 6 , wherein the protein is configured for uptake from the olfactory region in the upper posterior region within about 10 minutes following delivery.